Global Companion Diagnostic Markets Report 2021: A Steep Growth Curve Interrupted by COVID-19 – Forecast to 2025 – | Financial Buzz

Global Companion Diagnostic Markets Report 2021: A Steep Growth Curve Interrupted by COVID-19 – Forecast to 2025 –

The “Companion Diagnostic Markets – the Future of Diagnostics, by Funding Source and Application with Customized Forecasting/Analysis, COVID-19 Updates, and Executive and Consultant Guides 2021-2025” report has been added to’s offering.

Will Personalized Companion Diagnostics become the norm for diagnostics?

Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.

Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.

Key Topics Covered:

Companion Diagnostic Market – Strategic Situation Analysis

  • Guide for Executives, Marketing, Sales and Business Development Staff
  • Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

1.1 What are Companion Diagnostics?

1.2 The Personalized Medicine Revolution

1.3 Market Definition

1.4 Methodology

1.5 A Spending Perspective on Clinical Laboratory Testing

2. Market Overview

2.1 Players in a Dynamic Market

2.1.1 Academic Research Lab

2.1.2 Diagnostic Test Developer

2.1.3 Instrumentation Supplier

2.1.4 Distributor and Reagent Supplier

2.1.5 Independent Testing Lab

2.1.6 Public National/regional lab

2.1.7 Hospital lab

2.1.8 Physician Office Labs

2.1.9 Audit Body

2.1.10 Certification Body

2.2 Personalized Medicine and Companion Diagnostics

2.2.1 Basics

2.2.2 Method

2.2.3 Disease risk assessment

2.2.4 Applications

2.2.5 Diagnosis and intervention Companion Diagnostics

2.2.6 Drug development and usage

2.2.7 Respiratory proteomics

2.2.8 Cancer genomics

2.2.9 Population screening

2.2.10 Challenges

2.2.11 Regulatory oversight

2.2.12 Intellectual property rights

2.2.13 Reimbursement policies

2.2.14 Patient privacy and confidentiality

2.3 Chromosomes, Genes and Epigenetics

2.3.1 Chromosomes

2.3.2 Genes

2.3.3 Epigenetics

2.4 Cancer Genes

2.4.1 Germline vs Somatic

2.4.2 Changing Clinical Role

2.5 Structure of Industry Plays a Part

2.5.1 New Pharmaceutical Funding Market

2.5.2 Economies of Scale Hospital vs. Central Lab

2.5.3 Physician Office Labs

2.5.4 Physicians and POCT

3. Market Trends

3.1 Factors Driving Growth

3.1.1 Level of Care

3.1.2 Immuno-oncology

3.1.3 Liability

3.1.4 Aging Population

3.2 Factors Limiting Growth

3.2.1 State of knowledge

3.2.2 Genetic Blizzard.

3.2.3 Protocol Resistance

3.2.4 Regulation and coverage

3.3 Instrumentation and Automation

3.3.1 Instruments Key to Market Share

3.3.2 Bioinformatics Plays a Role

3.4 Diagnostic Technology Development

3.4.1 Next Generation Sequencing Fuels a Revolution.

3.4.2 Single Cell Genomics Changes the Picture

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 CGES Testing, A Brave New World

3.4.5 Biochips/Giant magneto resistance based assay

4. Companion Diagnostics Recent Developments

4.1 Recent Developments – Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

  • Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
  • FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies
  • Promega to Develop MSI Assay as CDx
  • HTG Molecular Q2 Revenues Drop 66 Percent
  • Guardant Health to Develop CDx for Janssen
  • Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx
  • FDA Approval for FoundationOneCDx
  • FDA finalizes CDx Guidance
  • QIAGEN Launches CDx Therascreen BRAF Test
  • Myriad Genetics Seeks Approval for Companion Diagnostic
  • ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
  • QIAGEN Builds on Global Collaboration with Amgen
  • Foundation Medicine nabs 19th companion Dx
  • Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
  • Myriad Wins Japanese Approval for BRACAnalysis
  • Fujitsu Improves Efficiency in Cancer Genomic Medicine
  • Thermo Fisher’s automated sequencer to offer same-day, pan-cancer test results
  • Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
  • Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
  • Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
  • Universal Genetic Testing for All Breast Cancer Patients
  • Exact Sciences buys Genomic Health
  • Biodesix Highlights Pipeline and Companion Diagnostic Development
  • Multi-Gene Liquid Biopsy Breast Cancer Panel
  • New Gene Panel Identifies High Risk Prostate Cancer
  • Guardant Health Liquid Biopsy Test to be Covered by EviCore
  • Inivata Completes 39.8M Series B Funding Round
  • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
  • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials

5. Profiles of Key Players

6. The Global Market for Companion Diagnostics

6.1 Global Market Overview by Country

6.2 Global Market by Application – Overview

6.3 Global Market Funding Source – Overview

7. Global Companion Diagnostic Markets – By Application

7.1 Oncology

7.2 Neurology

7.3 Cardiology

7.4 Other Application

8. Global Companion Diagnostic Markets – Funding Source

8.1 Global Market Pharmaceutical

8.2 Global Market Venture

8.3 Global Market Clinical

8.4 Global Market Other Funding

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900